Abstract
7529 Background: Hodgkin lymphoma (HL) is curable in the majority of cases without stem cell transplantation (SCT). However, patients(pts) who relapse after chemotherapy require autologousSCT, and about half of those pts relapse. For over 3 decades, allogeneic SCT has been implemented in more refractory HL pts. We present the long term follow up of a group of pts from a our institution who underwent alloSCT for HL. Methods: 21 pts with HL transplanted from 2008 to 2015 and disease characteristics (HL type, status at SCT, chemosensitivity), treatment( graft source, donor type, auto and allo SCTdates, GVHD prophylaxis ) and outcomes (maximum grade of acute and chronic GVHD, survival (OS) and causes of death) were analyzed. Results: 13 males and 8 females received an alloSCT from 2008 to 2015, 11 pts had Nodular sclerosis HL, 6 NOS, 2 mixed cellularity, 1 lymphocyte predominant and 1 lymphocyte depleted. Performance status was 60 to 100, median of 90. 16 grafts were unrelated and 5 HLA identical. 18 pts received PBSC, 2 bone marrow and one double cord transplant. Most pts, 19, had a prior autoSCT, one had 2 prior autoSCT and for one , the allo was the first SCT. One patient was transplanted in unconfirmed first CR, 2 in confirmed CR, 4 in PR without prior CR, 3 in 1strelapse, 5 in 2nd relapse, 5 in 3rd relapse, and one in primary induction failure. All patients had a reduce intensity conditioning: 14 Flu/Mel, 4 Flu/Mel ATG, and one each Flu/TBI/ATG, Flu/TBI, Flu/Cy. Acute GVHD happened in 11 pts: max grade I in 1 , II in 7, III in 1 and IV in 2. 6 pts had extensive chronic GVHD. 12 pts (57.1%) have died (survival range 0.65-43.45 months, mean 13.1, median 6.12). Causes of death were primary disease in 4, infection in 3 pts, GVHD and infection in 2, ARDS, organ failure, pulmonary toxicity in 1 each. 9 pts (42.8%) are alive (survival range 1.63-8.44 years, mean 4.97, median 4.47) Conclusions: AlloSCT for pts with relapsed HL is a feasible treatment modality that can lead to long term OS in a significant proportion of pts. Our data is comparable with other published studies for HL alloSCT. The utility of alloSCT should not be dismissed even in the age of Brentuximab and checkpoint inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
